SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly earnings beat, first profit since its IPO, and sharp growth in AI-compute revenue have fueled bullish reactions and short-squeeze chatter. Traders are also debating whether the growth outlook justifies the valuation given heavy AI infrastructure spending.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal Q1 update, citing stronger AI-platform demand, lifted its revenue outlook and projected higher gross margins than its prior guidance. Traders reacted bullishly and discussed possible short covering, while some questioned whether the stronger demand and margins will hold and whether the company can sustain confidence in its results.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly report drew attention as an earnings beat was overshadowed by softer forward guidance, slowing revenue growth and a reduced advertising outlook, prompting a sharp selloff. Traders debated whether the decline was overdone given the companys profitability and buybacks or a sign that growth and engagement are weakening amid streaming competition.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Musks confirmation that Tesla and SpaceX formed committees to explore a potential merger has fueled speculation, though traders emphasize that no deal is assured and disagree over whether a combination would benefit Tesla. The discussion is also shaped by Teslas upcoming quarterly results, with bulls positioning for a positive surprise and skeptics warning of a sell-the-news reaction and stretched valuation.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharp pullback and volatile rebound are driving discussion, with traders weighing JPMorgans upgrade to Neutral against the upcoming earnings report. Bulls point to potential foundry customers and AI partnerships, while skeptics question whether those largely unconfirmed developments justify the optimism or whether the bounce will hold.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is moving with the volatile AI-neocloud trade: traders linked a rebound to upbeat SpaceX commentary on compute demand, while persistent concerns about financing costs, debt exposure and weakness in peers such as CoreWeave fuel skepticism. Bulls argue AI infrastructure demand remains strong and Nebius is better positioned than some competitors; bears see sector-wide funding risks weighing on the shares.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff and underperformance versus other neocloud stocks have fueled debate over AI-infrastructure funding risks and the companys execution; CEO Daniel Roberts pushed back on debt concerns, saying its data centers were funded with cash and customer prepayments help cover GPU costs. Bulls point to strong compute demand and oversold conditions, while bears remain concerned about persistent weakness, dilution and data-center delivery timelines.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is drawing attention as traders position around the Phase 3 REGAL trials anticipated 80th-event trigger and eventual final analysis; the last disclosed count was 78, and no new event or readout is confirmed here. Some interpret the CEOs upbeat anniversary comments and other perceived signals as hints of a potential buyout, while skeptics view the rebound as volatile trading without fresh news.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reported orders from ByteDance, Alibaba and Tencent for more than $35 billion in export-compliant Nvidia GPUs have traders focused on Chinese demand, though Nvidia may be unable to fulfill most of them. The community sees the orders as evidence of strong AI-chip demand but debates why the news has not lifted shares, amid broader concerns about AI spending and financing.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal-testing business to Labcorp for cash is driving a sharp rally, with traders focused on the substantial proceeds and how they could support the remaining cancer-testing business. The reaction is divided: some view the deal as a balance-sheet and strategic positive, while others worry the divestiture removes revenue from a business already facing operational and debt concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Implied Volatility Surging for ANI Pharmaceuticals Stock Options

Investors need to pay close attention to ANIP stock based on the movements in the options market lately.

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.read more...

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals, Inc. Profit Climbs In Q2

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) revealed earnings for its second quarter that Increases, from the same period last year...

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI Pharmaceuticals Inc

ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors

Equity

Neutral Sentiment

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani dismissed the impact of tariffs on the company, stating that over 90% of the total revenues come from finished goods manufactured in the U.S.“While we await the administration's pharmaceutical industry-specific framework, it is worth reiterating ANI's long-standing commitment to the U.S. Pharmaceutical industry and our positive and unique positioning relative to our peers,” the CEO said during the earnings call on Friday. “Products representing less than 5% of our total company revenues rely directly on imports from China. In addition, we have a strong balance sheet that enables us to carry healthy levels of finished goods and raw material inventories.”On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANIP">ANIP</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1334/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_08_at_12_37_09_PM_png_c2361a1206.webp" alt="ANIP's Sentiment Meter and Message Volume as of 12:35 p.m. ET on Aug. 8, 2025 | Source: Stocktwits" width="1334" height="128"><figcaption>ANIP's Sentiment Meter and Message Volume as of 12:35 p.m. ET on Aug. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company is “practically” 100% American-produced and based to help pacify any government demands.<stembedurl>https://stocktwits.com/Dy2ski/message/624331368</stembedurl>ANI Pharmaceuticals on Friday reported second-quarter net revenues of $211.4 million, representing year-over-year growth of 53.1%, and above an analyst estimate of $190.11 million, according to Fiscal AI data. The company attributed the increase in revenue to a doubling in net revenues from its rare diseases product segment to $104 million. Adjusted and diluted earnings per share came in at $1.80, above an expected $1.42. &nbsp;&nbsp;&nbsp;&nbsp;The company also raised its full-year guidance. ANI now expects full year net revenue of $818 million to $843 million and adjusted EPS of $6.98 to $7.35. The firm added that it expects its rare diseases portfolio to represent about 50% of its total net revenue in 2025.Piper Sandler analyst David Amsellem subsequently raised the firm's price target on ANI Pharmaceuticals to $94 from $80 while keeping an ‘Overweight’ rating on the shares.ANIP stock is up by 49% this year and by about 46% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-procures-rideshare-permit-in-texas/chrnKvjRd4I">Tesla Procures Rideshare Permit In Texas: Retail Expects Stock To Trade Over $330 Until Next Major Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ANI said it expects full-year net revenue of $818 million to $843 million and adjusted EPS of $6.98 to $7.35.

Vanguard Group, Inc. - Vanguard U.S. Multifactor ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ANIP 🏥 

ANI Pharmaceuticals, Inc. announced positive Phase 4 SYNCHRONICITY trial results showing statistically significant improvements in BCVA letter score and CST at 6 months, maintained at 24 months in patients with chronic NIU-PS. 

Actionable market event

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANIP ANI Pharmaceuticals Inc

Fundamentals

Latest ANIP News